- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2016.
- Why 3/10
- Inflectra is an already-approved, marketed biosimilar with no pending PDUFA date, pivotal readout, or other binary regulatory catalyst scheduled. The EU marketing authorization was withdrawn in May 2026. As a small part of Pfizer's ~$63B revenue base, even major commercial shifts in this product would not drive a meaningful share-price move for PFE.
Inflectra is a mature, approved biosimilar with no pending regulatory catalysts. The key events to watch are Pfizer's quarterly biosimilar segment revenue trends and any further market-share shifts in the infliximab biosimilar category, but these are gradual commercial developments, not binary stock-moving catalysts for a company of Pfizer's size.
Price Chart
Executive Summary
Inflectra (infliximab-dyyb) is a biosimilar to Johnson & Johnson's Remicade, approved by the FDA in 2016 as the first biosimilar monoclonal antibody in the US. Developed by South Korea's Celltrion, Pfizer holds exclusive US commercialization rights. The drug treats multiple autoimmune diseases including rheumatoid arthritis, Crohn's disease, and psoriasis. While Inflectra holds about 30% of the US infliximab biosimilar market, it is a mature product with no pending regulatory catalysts. Pfizer has been winding down its Inflectra involvement outside the US: it voluntarily withdrew the EU marketing authorization in May 2026 for commercial reasons, and the product was discontinued in Canada in September 2025 (rebranded as Remdantry by Celltrion). A Class II recall was also initiated in January 2025 for a cGMP deviation. For Pfizer, Inflectra is one of several biosimilars in a portfolio that represents a very small fraction of the company's ~$63 billion annual revenue, making it a negligible stock-moving factor for the stock.
How It Works
Inflectra is a biosimilar version of infliximab (Remicade), a monoclonal antibody that blocks tumor necrosis factor alpha (TNF-alpha), a protein that drives inflammation in autoimmune diseases. By neutralizing TNF-alpha, it reduces inflammation and symptoms in conditions like rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is given as an intravenous infusion.
Trial Status
Inflectra was approved by the FDA on April 5, 2016, based on clinical data demonstrating biosimilarity to Remicade (infliximab). It is a commercially marketed product with no ongoing pivotal trials for the IV formulation. A subcutaneous formulation (Zymfentra) was later approved separately by Celltrion.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates, FDA advisory committee meetings, or pivotal readouts are scheduled for Inflectra. The EU marketing authorization was withdrawn in May 2026. Future developments would be limited to routine commercial updates in Pfizer's quarterly earnings reports.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report